(PBH) Prestige Brand Holdings - NYSE
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NYSE (USA) | Market Cap: 2.265m USD | Total Return: -44.9% in 12m
Avg Turnover: 31.0M
EPS Trend: 33.5%
Qual. Beats: -1
Rev. Trend: -70.1%
Qual. Beats: -1
Warnings
Fakeout Below Avwap Earnings
Tailwinds
No distinct edge detected
Prestige Consumer Healthcare Inc. (PBH) specializes in the development, marketing, and distribution of over-the-counter (OTC) health and personal care products. The company manages a portfolio of established brands across categories such as pediatrics, eye care, women’s health, and gastrointestinal relief. Key brands include Monistat, Clear Eyes, Dramamine, and Fleet. Prestige operates primarily through two segments: North American OTC Healthcare and International OTC Healthcare.
The company utilizes an asset-light business model, often outsourcing manufacturing to third-party providers to maintain focus on brand management and retail distribution. The OTC sector is characterized by high consumer loyalty and stable demand, as many products address non-discretionary health needs. PBH distributes its products through diverse channels, including mass merchandisers, drug stores, and e-commerce platforms.
Investors may find it useful to examine ValueRay for deeper insights into the company’s valuation metrics.
- Strategic brand acquisitions drive inorganic revenue growth and market share expansion
- Consumer health spending patterns influence core North American OTC segment revenue
- Supply chain efficiency and raw material costs impact consolidated gross margins
- E-commerce channel penetration accelerates sales growth within the International OTC segment
- High leverage levels make interest rate fluctuations a key earnings variable
| Net Income: 190.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 0.02 > 1.0 |
| NWC/Revenue: 28.53% < 20% (prev 30.03%; Δ -1.51% < -1%) |
| CFO/TA 0.07 > 3% & CFO 265.4m > Net Income 190.3m |
| Net Debt (1.03b) to EBITDA (331.1m): 3.11 < 3 |
| Current Ratio: 3.57 > 1.5 & < 3 |
| Outstanding Shares: last quarter (47.7m) vs 12m ago -4.78% < -2% |
| Gross Margin: 53.96% > 18% (prev 56.27%; Δ -2.31% > 0.5%) |
| Asset Turnover: 31.33% > 50% (prev 33.44%; Δ -2.11% > 0%) |
| Interest Coverage Ratio: 7.08 > 6 (EBIT TTM 299.8m / Interest Expense TTM 42.3m) |
| A: 0.09 (Total Current Assets 431.5m - Total Current Liabilities 120.9m) / Total Assets 3.55b |
| B: 0.49 (Retained Earnings 1.75b / Total Assets 3.55b) |
| C: 0.09 (EBIT TTM 299.8m / Avg Total Assets 3.47b) |
| D: 1.14 (Book Value of Equity 1.89b / Total Liabilities 1.66b) |
| Altman-Z'' = 3.95 = AA |
| DSRI: 1.03 (Receivables 191.9m/194.3m, Revenue 1.09b/1.14b) |
| GMI: 1.04 (GM 56.27% / 53.96%) |
| AQI: 1.00 (AQ_t 0.83 / AQ_t-1 0.83) |
| SGI: 0.96 (Revenue 1.09b / 1.14b) |
| TATA: -0.02 (NI 190.3m - CFO 265.4m) / TA 3.55b) |
| Beneish M = -2.99 (Cap -4..+1) = A |
As of June 18, 2026, the stock is trading at USD 46.14 with a total of 781,023 shares traded.
Over the past week, the price has changed by -6.09%,
over one month by -0.99%,
over three months by -25.94% and
over the past year by -44.86%.
Prestige Brand Holdings has received a consensus analysts rating of 3.71. Therefore, it is recommended to hold PBH.
- StrongBuy: 3
- Buy: 0
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 66.8 | 44.8% |
P/E Trailing = 12.2302
P/E Forward = 10.5932
P/S = 2.0808
P/B = 1.1939
P/EG = 1.4414
Revenue TTM = 1.09b USD
EBIT TTM = 299.8m USD
EBITDA TTM = 331.1m USD
Long Term Debt = 994.0m USD (from longTermDebt, last quarter)
Short Term Debt = 12.6m USD (from shortTermDebt, last quarter)
Debt = 1.09b USD (from shortLongTermDebtTotal, last quarter) + Leases 48.5m
Net Debt = 1.03b USD (calculated: Debt 1.09b - CCE 63.9m)
Enterprise Value = 3.30b USD (2.27b + Debt 1.09b - CCE 63.9m)
Interest Coverage Ratio = 7.08 (Ebit TTM 299.8m / Interest Expense TTM 42.3m)
EV/FCF = 12.96x (Enterprise Value 3.30b / FCF TTM 254.2m)
FCF Yield = 7.71% (FCF TTM 254.2m / Enterprise Value 3.30b)
FCF Margin = 23.35% (FCF TTM 254.2m / Revenue TTM 1.09b)
Net Margin = 17.48% (Net Income TTM 190.3m / Revenue TTM 1.09b)
Gross Margin = 53.96% ((Revenue TTM 1.09b - Cost of Revenue TTM 501.3m) / Revenue TTM)
Gross Margin QoQ = 50.02% (prev 55.52%)
Tobins Q-Ratio = 0.93 (Enterprise Value 3.30b / Total Assets 3.55b)
Interest Expense / Debt = 3.87% (Interest Expense 42.3m / Debt 1.09b)
Taxrate = 26.10% (67.2m / 257.5m)
NOPAT = 221.6m (EBIT 299.8m * (1 - 26.10%))
Current Ratio = 3.57 (Total Current Assets 431.5m / Total Current Liabilities 120.9m)
Debt / Equity = 0.58 (Debt 1.09b / totalStockholderEquity, last quarter 1.89b)
Debt / EBITDA = 3.11 (Net Debt 1.03b / EBITDA 331.1m)
Debt / FCF = 4.05 (Net Debt 1.03b / FCF TTM 254.2m)
Total Stockholder Equity = 1.85b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.48% (Net Income 190.3m / Total Assets 3.55b)
RoE = 10.29% (Net Income TTM 190.3m / Total Stockholder Equity 1.85b)
RoCE = 10.55% (EBIT 299.8m / Capital Employed (Equity 1.85b + L.T.Debt 994.0m))
RoIC = 6.55% (NOPAT 221.6m / Invested Capital 3.38b)
WACC = 5.46% (E(2.27b)/V(3.36b) * Re(6.72%) + D(1.09b)/V(3.36b) * Rd(3.87%) * (1-Tc(0.26)))
Discount Rate = 6.72% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -82.22 | Cagr: -2.19%
[DCF] Terminal Value 76.02% ; FCFF base≈249.9m ; Y1≈260.3m ; Y5≈296.7m
[DCF] Fair Price = 74.91 (EV 4.58b - Net Debt 1.03b = Equity 3.55b / Shares 47.4m; r=8.35% [WACC [floored]]; 5y FCF grow 4.50% → 2.50% )
EPS Correlation: 33.49 | EPS CAGR: 1.38% | SUE: -2.37 | # QB: -1
Revenue Correlation: -70.07 | Revenue CAGR: -0.97% | SUE: -1.28 | # QB: -1
EPS current Quarter (2026-06-30): EPS=0.87 | Chg30d=-12.12% | Revisions=-43% | Analysts=5
EPS next Quarter (2026-09-30): EPS=1.15 | Chg30d=+0.22% | Revisions=-20% | Analysts=2
EPS current Year (2027-03-31): EPS=4.61 | Chg30d=-4.13% | Revisions=-64% | GrowthEPS=+5.2% | GrowthRev=+12.8%
EPS next Year (2028-03-31): EPS=5.02 | Chg30d=-0.51% | Revisions=-20% | GrowthEPS=+8.9% | GrowthRev=+8.0%
[Analyst] Revisions Ratio: -64%